# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN
- Date: 2026-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Sixteen-week review after the sick visit. **S**

## History of present illness

Sugar Ray Robinson returns sixteen weeks after intake with his care partner, four weeks after the sick visit for nausea, loose stools and a slow pulse on donepezil 10 mg. Since returning to 5 mg in the morning his stomach has settled, the vivid dreams stopped, and he has not been dizzy. Metformin and lisinopril were restarted after two days. He had the dilated eye examination two weeks ago, with no retinopathy. He goes to the day program twice a week and to the foundation gym once. His care partner is sleeping better with the day program and the caregiver class. **S**

| Element | Detail |
|---|---|
| Donepezil | 5 mg each morning; no side effects |
| Creatinine | 1.0 mg/dL, from 1.2 at the sick visit |
| Eye examination | No diabetic retinopathy |
| PHQ-9 | 3 |
| Care partner | Zarit 16, narrative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea or diarrhea |
| Cardiovascular | Negative | No dizziness or fainting |
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Lisinopril 20 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Donepezil 5 mg oral tablet, one tablet each morning with breakfast **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 75.8 kg; BMI 23.4 kg/m². All vital signs are synthetic.

Potassium: 4.4 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 85 mL/min/1.73 m²; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Potassium: 4.4 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 85 mL/min/1.73 m² at baseline, 85 mL/min/1.73 m² at this visit **S**
- PHQ-9: 4 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/76 seated and 124/74 standing; pulse 66 and regular; weight 75.8 kg |
| Mouth | Moist mucous membranes |
| Mental status | Cheerful and engaged; repeats a story once |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Alzheimer's disease with early onset** (G30.0). Donepezil 5 mg each morning is tolerated; 10 mg was not. He and his care partner prefer to stay at 5 mg for now rather than retry 10 mg or switch to a rivastigmine patch. Memantine is not indicated at the mild stage. **S**
   - Continue donepezil 5 mg each morning.
   - MoCA and CDR in six to twelve months.
   - Revisit the dose, or a rivastigmine patch, if he declines.
2. **Type 2 diabetes** (E11.9). Kidney function back to baseline; no retinopathy. **S**
   - Continue metformin with sick-day rules.
   - Hemoglobin A1c in five months; eye examination in one to two years.
3. **Mild dementia due to Alzheimer's disease** (F02.A0). Stable; no behavioral symptoms; safe at home with the day program; care partner strain lower. **S**
   - Continue the day program and the caregiver class.
   - GUIDE dementia care program when he has Medicare.
   - Advance care plan reviewed in six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Up to date | Next in six to twelve months |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | No anticholinergic or sedating drugs |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Completed today | 5 mg each morning tolerated; pulse 66; 10 mg not tolerated (sick visit) |
| Survey | Depression screen (PHQ-9) | At diagnosis and yearly | Completed today | 3; item 9 scored 0 |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Not driving; no firearm in the home; no wandering |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Completed today | Zarit 16, from 18; day program and caregiver class |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Up to date | 6.9% five weeks ago; no low readings |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 126/76 mmHg; no standing drop |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Completed today | Potassium 4.4 mmol/L, creatinine 1.0 mg/dL (eGFR 85), back to baseline after the dehydration |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Completed today | Dilated examination two weeks ago: no retinopathy |
| Self-management | Exercise and social activity | Every visit | Completed today | Day program exercise, daily walks and the foundation gym |

## Goal progress

- Find the cause of the memory loss and explain it to him in a way he can take in. Outcome by 2026-08-18: Alzheimer's disease confirmed by amyloid PET; disclosed with his care partner present, at his request, with written notes. **S**
- No hypoglycemia, with hemoglobin A1c under 8.0%. Outcome by 2026-10-27: Glipizide stopped after one reading of 68 mg/dL; no low readings since; A1c 6.4 to 6.9%. **S**
- Stay safe: no driving and no firearm in the home. Outcome by 2026-08-18: He stopped driving and the handgun was removed from the home. **S**
- Keep his days full and give his care partner regular breaks. Outcome by 2026-10-27: Adult day program two days a week; walks and the foundation gym on other days; Alzheimer's Association helpline. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026), Aether Forge
- 13. Older Adults: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S277-S296)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Practice Parameter update: Evaluation and management of driving risk in dementia (2010), American Academy of Neurology (Neurology 2010;74(16):1316-1324)
- Guiding an Improved Dementia Experience (GUIDE) Model (2024), Centers for Medicare & Medicaid Services, Innovation Center

## Follow-up

- Second recombinant zoster dose due two to six months after the first. Review in three months. Call for side effects, falls, low glucose readings or new behavior changes. **S**

